JP Morgan maintains Overweight recommendation on Allogene Therapeutics amid bullish market sentiment
On Monday, financial services firm JP Morgan continued its coverage of clinical-stage biotech company Allogene Therapeutics (NASDAQ:ALLO), issuing an Overweight recommendation. The one-year price target for Allogene Therapeutics is predicted to average at $17.27, indicating a potential upside of 373.20% from its last reported closing price of $3.65.
The company's estimated annual revenue is projected to rise by a significant 1,975.52% to $4 million, despite expectations of a non-GAAP EPS of -2.83. In the latest quarter, the number of funds or institutions holding positions in Allogene Therapeutics stood at 383, marking a decrease of 2.79% from the previous quarter. The average portfolio weight dedicated to ALLO has also dropped by 6.79% to 0.10%. However, the total shares owned by institutions have risen by 8.53% over the last three months to 141.84 million shares.
In terms of market sentiment, the put/call ratio for ALLO is currently at 0.28, suggesting bullishness in the market.
Several key shareholders have been adjusting their stakes in Allogene Therapeutics. Tpg Gp A holds a significant stake in the company with 18.716 million shares, accounting for 11.17% ownership, unchanged from the previous quarter.
SPDR(R) S&P(R) Biotech ETF increased its holdings by 4.75%, now owning 6.591 million shares or 3.93% of the company, which represents a portfolio allocation increase of 5.13%.
Jpmorgan Chase boosted its stake by 18.09% to hold 6.134 million shares, representing 3.66% ownership of the company. This increase also led to a substantial rise of 772.58% in its portfolio allocation in ALLO.
However, Primecap Management and Price T Rowe Associates downsized their stakes by 2.35% and 18.74% respectively, corresponding with a reduction in portfolio allocation.
Allogene Therapeutics, based in South San Francisco, is leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer treatment. The company's goal is to provide 'off-the-shelf' CAR T cell therapy candidates that are readily available, reliable, and scalable to benefit more patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Related Articles
JP Morgan maintains Overweight recommendation on Allogene Therapeutics amid bullish market sentiment
Qualcomm plans downsizing amidst economic uncertainties, denies shutting China R&D facility
